Every year around 500,000 people in Germany are diagnosed with cancer. This makes it all the more important to research new therapy options.
New active ingredients based on so-called low molecules, i.e. with a mass of less than 800 g/mol, are intended to offer new treatment options, especially for advanced cancers. Immunotherapies have only recently been approved for cancer therapy - including for the treatment of lung cancer, skin cancer, kidney cancer, bladder cancer and head and neck tumors.